AVOS Life Sciences

Table of Contents - Asthma/COPD

Disease Etiology 6
Asthma Disease Background 6
COPD Disease Background 6
Diagnosis 6
Epidemiology & Patient Population Estimates 8
Theoretical Patient Population 8
Addressable Patient Population 8
Treated Patient Population 8
Patient Compliance 8
Asthma 8
COPD 9
Asthma/COPD Patient Population Model 10
Disease & Market Definitions 11
Asthma 11
COPD 11
Forecasting Methodologies 12
Market Revenue Forecasts 12
U.S. Asthma/COPD Market Model, 2004-2013 14
AVOS Physician Panel Results 16
Physician Treatment Patterns 16
Patient Compliance 17
Cost 17
Asymptomatic Nature 17
Dosing 17
Physician Product Selection Criteria 18
Historical Physician Use Patterns 18
Delivery Device 18
Dosing 18
Sampling 18
Approaches to Differentiation 18
Pregnancy Rating 19
Device Improvements 19
Administration Options 19
Physician Product Ratings & Forecasts of Future Market Trends 19
Physician Panel Market Trend Forecasts 20
Market Overview 24
Leading Products 24
Current Market Environment 25
Product Profiles
Advair 26
U.S. Perspective 26
Worldwide Perspective 27
AVOS Physician Panel Discussions 27
Symbicort 29
U.S. Perspective 29
Worldwide Perspective 30
AVOS Physician Panel Discussions 30
Spiriva 31
U.S. Perspective 31
Worldwide Perspective 32
AVOS Physician Panel Discussions 32
Atrovent / Combivent 33
U.S. Perspective 33
Worldwide Perspective 34
AVOS Physician Panel Discussions 34
Singulair 35
U.S. Perspective 35
Worldwide Perspective 36
AVOS Physician Panel Discussions 36
Xolair 37
U.S. Perspective 37
Worldwide Perspective 37
AVOS Physician Panel Discussions 38
Asmanex 39
U.S. Perspective 39
Worldwide Perspective 40
AVOS Physician Panel Discussions 40
Pulmicort 41
U.S. Perspective 41
Worldwide Perspective 42
AVOS Physician Panel Discussions 42
Flovent 43
U.S. Perspective 43
Worldwide Perspective 43
AVOS Physician Panel Discussions 44
Serevent 45
U.S. Perspective 45
Worldwide Perspective 46
AVOS Physician Panel Discussions 46
Foradil 47
U.S. Perspective 47
Worldwide Perspective 48
AVOS Physician Panel Discussions 48
Brovana 49
U.S. Perspective 49
Worldwide Perspective 50
AVOS Physician Panel Discussions 50
Albuterol / ProAir HFA / Proventil HFA 51
U.S. Perspective 51
Worldwide Perspective 52
AVOS Physician Panel Discussions 52
Pipeline Product Profiles
Xopenex HFA 53
U.S. Perspective 53
Worldwide Perspective 54
AVOS Physician Panel Discussions 54
Alvesco 55
U.S. Perspective 55
Worldwide Perspective 55
AVOS Physician Panel Discussions 56
Aclidinium Bromide / Bretaris 57
U.S. Perspective 57
Worldwide Perspective 57
AVOS Physician Panel Discussions 57
Indacterol 58
U.S. Perspective 58
Worldwide Perspective 59
AVOS Physician Panel Discussions 59
Flutiform 60
U.S. Perspective 60
Worldwide Perspective 60
AVOS Physician Panel Discussions 60
Asmanex + Foradil 62
U.S. Perspective 62
Worldwide Perspective 62
AVOS Physician Panel Discussions 62
Drugs in Development 63
R&D Overview 63
Assessment of R&D Success Rates 63
Products in the Pipeline 65
Registration (one agent) 65
Pre-Registration (one agent) 65
Phase III (five agents) 65
Phase II (seven agents) 65
Cover

Production date: November 2007

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com